Anthony  Doyle net worth and biography

Anthony Doyle Biography and Net Worth

Anthony Doyle serves as Chief Financial Officer, Senior Vice President of the Company. He joins the Company from Worldwide Clinical Trials Holdings, Inc. (“WCT”), a full service global contract research organization, where he served as Chief Financial Officer since 2014. From 2004 to 2012, Mr. Doyle held a series of increasingly responsible roles at General Electric, moving through financial planning & analysis, controller, audit, tax and commercial finance rotations in the GE Financial Management and Corporate Audit Staff finance and leadership training programs. He then led risk and pricing for GE Healthcare’s $1.2 billion U.S. diagnostic imaging business and served as global program manager for GE Healthcare Solutions, a hospital and healthcare outcomes-based consulting company. From 2012 to 2014, he was CFO of World Book, a Berkshire Hathaway company. Mr. Doyle completed his Bachelor’s degree from Dublin City University (Ireland) and his DESEM from Reims Management School (France). Mr. Doyle also has a Graduate Certificate in Corporate Treasury from Dublin City University.

What is Anthony Doyle's net worth?

The estimated net worth of Anthony Doyle is at least $1.90 million as of May 14th, 2024. Mr. Doyle owns 266,744 shares of BioCryst Pharmaceuticals stock worth more than $1,904,552 as of July 21st. This net worth estimate does not reflect any other assets that Mr. Doyle may own. Additionally, Mr. Doyle receives an annual salary of $845,930.00 as CFO at BioCryst Pharmaceuticals. Learn More about Anthony Doyle's net worth.

How old is Anthony Doyle?

Mr. Doyle is currently 44 years old. There are 2 older executives and no younger executives at BioCryst Pharmaceuticals. The oldest executive at BioCryst Pharmaceuticals is Mr. Jon P. Stonehouse, CEO, President & Executive Director, who is 63 years old. Learn More on Anthony Doyle's age.

What is Anthony Doyle's salary?

As the CFO of BioCryst Pharmaceuticals, Inc., Mr. Doyle earns $845,930.00 per year. The highest earning executive at BioCryst Pharmaceuticals is Mr. Jon P. Stonehouse, CEO, President & Executive Director, who commands a salary of $1,230,000.00 per year. Learn More on Anthony Doyle's salary.

How do I contact Anthony Doyle?

The corporate mailing address for Mr. Doyle and other BioCryst Pharmaceuticals executives is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. BioCryst Pharmaceuticals can also be reached via phone at (919) 859-1302 and via email at [email protected]. Learn More on Anthony Doyle's contact information.

Has Anthony Doyle been buying or selling shares of BioCryst Pharmaceuticals?

Anthony Doyle has not been actively trading shares of BioCryst Pharmaceuticals during the past quarter. Most recently, on Tuesday, May 14th, Anthony Doyle bought 36,300 shares of BioCryst Pharmaceuticals stock. The stock was acquired at an average cost of $5.57 per share, with a total value of $202,191.00. Following the completion of the transaction, the chief financial officer now directly owns 266,744 shares of the company's stock, valued at $1,485,764.08. Learn More on Anthony Doyle's trading history.

Who are BioCryst Pharmaceuticals' active insiders?

BioCryst Pharmaceuticals' insider roster includes George Abercrombie (Director), Yarlagadda Babu (Insider), Alane Barnes (Insider), Anthony Doyle (CFO), Nancy Hutson (Director), Vincent Milano (Director), William Sheridan (Insider), and Jon Stonehouse (CEO). Learn More on BioCryst Pharmaceuticals' active insiders.

Are insiders buying or selling shares of BioCryst Pharmaceuticals?

During the last twelve months, BioCryst Pharmaceuticals insiders bought shares 6 times. They purchased a total of 103,601 shares worth more than $596,337.56. During the last twelve months, insiders at the biotechnology company sold shares 2 times. They sold a total of 13,289 shares worth more than $82,486.00. The most recent insider tranaction occured on June, 24th when Director Amy E Mckee sold 8,600 shares worth more than $54,352.00. Insiders at BioCryst Pharmaceuticals own 4.8% of the company. Learn More about insider trades at BioCryst Pharmaceuticals.

Information on this page was last updated on 6/24/2024.

Anthony Doyle Insider Trading History at BioCryst Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/14/2024Buy36,300$5.57$202,191.00266,744View SEC Filing Icon  
12/15/2022Sell5,700$10.90$62,130.00163,966View SEC Filing Icon  
11/23/2021Buy35,258$12.48$440,019.84View SEC Filing Icon  
8/11/2020Buy54,000$4.08$220,320.0054,000View SEC Filing Icon  
See Full Table

Anthony Doyle Buying and Selling Activity at BioCryst Pharmaceuticals

This chart shows Anthony Doyle's buying and selling at BioCryst Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BioCryst Pharmaceuticals Company Overview

BioCryst Pharmaceuticals logo
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Read More

Today's Range

Now: $7.14
Low: $7.02
High: $7.28

50 Day Range

MA: $6.44
Low: $5.36
High: $7.63

2 Week Range

Now: $7.14
Low: $4.03
High: $7.95

Volume

1,629,652 shs

Average Volume

3,454,248 shs

Market Capitalization

$1.47 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.88